Sodium Dichloroacetate丨CAS 2156-56-1

Sdium dichlracetate丨2156-56-1 is a chlrinated rganic cmpund that is widely studied fr its ptential therapeutic and bichemical prperties. It is the sdium salt f dichlracetic acid (DCA) and has attracted attentin fr its ability t mdulate cellular metablism, particularly by influencing lactate metablism and mitchndrial functin.

Sdium dichlracetate丨2156-56-1 primarily exerts its effects by mdulating cellular metablism, especially in the cntext f lactate prductin and aerbic respiratin.
● Inhibitin f Pyruvate Dehydrgenase Kinase (PDK): Sdium dichlracetate丨2156-56-1 inhibits the pyruvate dehydrgenase kinase (PDK) enzyme, which in turn activates pyruvate dehydrgenase (PDH). This leads t increased cnversin f pyruvate int acetyl-CA, which enters the Krebs cycle (TCA cycle) fr xidative phsphrylatin in mitchndria. This shift frm anaerbic glyclysis t aerbic metablism is beneficial in cnditins where lactate accumulatin and hypxia ccur.

● Mitchndrial Functin: Sdium dichlracetate丨2156-56-1 has been shwn t enhance mitchndrial functin by prmting xidative phsphrylatin, which leads t mre efficient ATP prductin. This can have therapeutic ptential in diseases where mitchndrial dysfunctin is a factr, such as in neurdegenerative diseases r cancer.

1.Cancer Therapy:
Targeting Tumr Metablism: Sdium dichlracetate丨2156-56-1 has gained interest in cancer research due t its ability t shift cancer cell metablism frm anaerbic glyclysis (the Warburg effect) t aerbic respiratin. Many cancer cells rely heavily n glyclysis fr energy prductin, even in the presence f xygen (knwn as the Warburg effect). By prmting mitchndrial xidative phsphrylatin, sdium dichlracetate culd reduce tumr grwth and metastasis.

2.Lactic Acidsis:

3.Mitchndrial Diseases:


4.Diabetes:
Sme research suggests that sdium dichlracetate may have ptential in type 2 diabetes by imprving insulin sensitivity and glyclytic metablism. It may help balance glucse metablism, making it a ptential candidate fr diabetes management, althugh its use fr this purpse requires further investigatin.
5.Acid-Base Balance:
Sdium dichlracetate丨2156-56-1 may be used experimentally t help balance acid-base disrders by reducing acid buildup in the bdy, which can be beneficial in cnditins like chrnic kidney disease and renal acidsis.

1.Targeted Metabolic Effect:

Sodium dichloroacetate丨2156-56-1 specifically targets pyruvate metabolism and mitochondrial function, making it a precise therapeutic agent for diseases associated with metabolic dysregulation.

2.Reduction of Lactic Acid:

By decreasing lactate production, Sodium dichloroacetate丨2156-56-1 can help reduce lactic acidosis, a potentially dangerous condition seen in metabolic disorders, cancers, and critical care settings.

3.Cancer Treatment Potential:

4.Mitochondrial Support:

5.Low Toxicity:

Sodium dichloroacetate丨2156-56-1 is a metabolic modulator with significant potential in the treatment of metabolic disorders, cancer, lactic acidosis, and mitochondrial diseases. By altering pyruvate metabolism and enhancing mitochondrial function, it offers a unique approach to treating conditions where metabolic dysregulation plays a critical role. While the compound shows promise in several therapeutic areas, its use must be carefully monitored due to potential liver toxicity and neurological side effects. Ongoing research is needed to establish its safety and efficacy in clinical practice.